{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:01:41Z","timestamp":1785391301723,"version":"3.55.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Monogenic Pediatric systemic lupus erythematosus (SLE) secondary to complement deficiencies, including C1Q deficiency caused by C1QA mutations, is a rare and severe type of SLE that can be characterized by early onset and refractory disease. Inhibiting the interferon pathway has proved to be an effective treatment option, although there is little evidence in monogenic pediatric SLE. We describe a 10-year-old female with genetically-verified C1Q deficiency who had persistent and severe mucocutaneous disease, with recurrent skin rash, ulcerations, and oral sores, despite long-term immunosuppressive and biologic treatment. After a disease flare, the patient was started on anifrolumab, a monoclonal antibody against type I interferon receptor. She showed significant clinical improvement and full recovery of mucocutaneous lesions, restoration of laboratory parameters and successful discontinuation of corticosteroids after the seventh monthly infusion. It was well tolerated with no serious side effects. The case demonstrates the possible effectiveness and safety of anifrolumab in the treatment of refractory cutaneous manifestations in children with monogenic pediatric SLE, which is linked to interferon pathway dysregulation. Further studies are needed to establish its role in this population.<\/jats:p>","DOI":"10.3389\/fped.2026.1877919","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:39:59Z","timestamp":1785389999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interferon-targeted therapy with anifrolumab in monogenic pediatric systemic lupus erythematosus due to C1q deficiency: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Seham M.","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Pediatrics, College of Medicine, Najran University","place":["Najran, Saudi Arabia"]},{"name":"Department of Pediatrics, Division of Pediatric Rheumatology, Prince Sultan Medical Military City","place":["Riyadh, Saudi Arabia"]},{"name":"Health Research Center, Najran University","place":["Najran, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalrahman Mohammed","family":"Asiri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Rheumatology, Prince Sultan Medical Military City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Aljuaid","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Rheumatology, Prince Sultan Medical Military City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/annrheumdis-2023-eular.2607","article-title":"POS0135 Genetical and phenotypical findings of childhood-onset systemic lupus erythematosus","volume":"82","author":"Mor\u00e1n \u00c1lvarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","article-title":"The complement system and human autoimmune diseases","volume":"137","author":"Coss","year":"2023","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10875-024-01788-5","article-title":"Hereditary C1Q deficiency is associated with type 1 interferon-pathway activation and a high risk of central nervous system inflammation","volume":"44","author":"Triaille","year":"2024","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e63966","DOI":"10.7759\/cureus.63966","article-title":"Evaluation of the efficacy and safety of anifrolumab in moderate-to-severe systemic lupus erythematosus","volume":"16","author":"Cingireddy","year":"2024","journal-title":"Cureus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jvc2.590","article-title":"Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and dle (discoid lupus erythematosus)","volume":"4","author":"Parriel","year":"2025","journal-title":"JEADV Clin Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"T55","DOI":"10.1016\/j.ad.2024.10.008","article-title":"[Translated article] use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses","volume":"116","author":"Mart\u00edn-Torregrosa","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (anifrolumab) in patients with type I interferonopathies","volume":"45","author":"Kretzschmar","year":"2025","journal-title":"J Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/1346-8138.17027","article-title":"Anifrolumab for systemic lupus erythematosus: a clinical study of Japanese patients in Kanazawa university hospital","volume":"51","author":"Fushida","year":"2024","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/09612033251330094","article-title":"Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus","volume":"34","author":"Shmizu","year":"2025","journal-title":"Lupus"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1877919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:40:00Z","timestamp":1785390000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1877919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":9,"alternative-id":["10.3389\/fped.2026.1877919"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1877919","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1877919"}}